Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

637 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Safety and Efficacy of Bimekizumab in Patients With Active Psoriatic Arthritis: Three-Year Results From a Phase IIb Randomized Controlled Trial and Its Open-Label Extension Study.
Coates LC, McInnes IB, Merola JF, Warren RB, Kavanaugh A, Gottlieb AB, Gossec L, Assudani D, Bajracharya R, Coarse J, Ink B, Ritchlin CT. Coates LC, et al. Among authors: mcinnes ib. Arthritis Rheumatol. 2022 Dec;74(12):1959-1970. doi: 10.1002/art.42280. Epub 2022 Nov 18. Arthritis Rheumatol. 2022. PMID: 35829656 Free PMC article. Clinical Trial.
Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study.
Kavanaugh A, McInnes I, Mease P, Krueger GG, Gladman D, Gomez-Reino J, Papp K, Zrubek J, Mudivarthy S, Mack M, Visvanathan S, Beutler A. Kavanaugh A, et al. Arthritis Rheum. 2009 Apr;60(4):976-86. doi: 10.1002/art.24403. Arthritis Rheum. 2009. PMID: 19333944 Free article. Clinical Trial.
European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies.
Gossec L, Smolen JS, Gaujoux-Viala C, Ash Z, Marzo-Ortega H, van der Heijde D, FitzGerald O, Aletaha D, Balint P, Boumpas D, Braun J, Breedveld FC, Burmester G, Cañete JD, de Wit M, Dagfinrud H, de Vlam K, Dougados M, Helliwell P, Kavanaugh A, Kvien TK, Landewé R, Luger T, Maccarone M, McGonagle D, McHugh N, McInnes IB, Ritchlin C, Sieper J, Tak PP, Valesini G, Vencovsky J, Winthrop KL, Zink A, Emery P; European League Against Rheumatism. Gossec L, et al. Among authors: mcinnes ib. Ann Rheum Dis. 2012 Jan;71(1):4-12. doi: 10.1136/annrheumdis-2011-200350. Epub 2011 Sep 27. Ann Rheum Dis. 2012. PMID: 21953336 Free article.
Golimumab in psoriatic arthritis: one-year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial.
Kavanaugh A, van der Heijde D, McInnes IB, Mease P, Krueger GG, Gladman DD, Gómez-Reino J, Papp K, Baratelle A, Xu W, Mudivarthy S, Mack M, Rahman MU, Xu Z, Zrubek J, Beutler A. Kavanaugh A, et al. Among authors: mcinnes ib. Arthritis Rheum. 2012 Aug;64(8):2504-17. doi: 10.1002/art.34436. Arthritis Rheum. 2012. PMID: 22378566 Free article. Clinical Trial.
Markers of inflammation and bone remodelling associated with improvement in clinical response measures in psoriatic arthritis patients treated with golimumab.
Wagner CL, Visvanathan S, Elashoff M, McInnes IB, Mease PJ, Krueger GG, Murphy FT, Papp K, Gomez-Reino JJ, Mack M, Beutler A, Gladman D, Kavanaugh A. Wagner CL, et al. Among authors: mcinnes ib. Ann Rheum Dis. 2013 Jan;72(1):83-8. doi: 10.1136/annrheumdis-2012-201697. Epub 2012 Sep 12. Ann Rheum Dis. 2013. PMID: 22975755 Free PMC article. Clinical Trial.
Clinical efficacy, radiographic and safety findings through 2 years of golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of the randomised, placebo-controlled GO-REVEAL study.
Kavanaugh A, McInnes IB, Mease PJ, Krueger GG, Gladman DD, van der Heijde D, Mudivarthy S, Xu W, Mack M, Xu Z, Beutler A. Kavanaugh A, et al. Among authors: mcinnes ib. Ann Rheum Dis. 2013 Nov;72(11):1777-85. doi: 10.1136/annrheumdis-2012-202035. Epub 2012 Nov 17. Ann Rheum Dis. 2013. PMID: 23161902 Free PMC article. Clinical Trial.
Patient-reported outcomes and the association with clinical response in patients with active psoriatic arthritis treated with golimumab: findings through 2 years of a phase III, multicenter, randomized, double-blind, placebo-controlled trial.
Kavanaugh A, McInnes IB, Krueger GG, Gladman D, Beutler A, Gathany T, Mack M, Tandon N, Han C, Mease P. Kavanaugh A, et al. Among authors: mcinnes ib. Arthritis Care Res (Hoboken). 2013 Oct;65(10):1666-73. doi: 10.1002/acr.22044. Arthritis Care Res (Hoboken). 2013. PMID: 23666608 Free PMC article. Clinical Trial.
Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial.
McInnes IB, Kavanaugh A, Gottlieb AB, Puig L, Rahman P, Ritchlin C, Brodmerkel C, Li S, Wang Y, Mendelsohn AM, Doyle MK; PSUMMIT 1 Study Group. McInnes IB, et al. Lancet. 2013 Aug 31;382(9894):780-9. doi: 10.1016/S0140-6736(13)60594-2. Epub 2013 Jun 13. Lancet. 2013. PMID: 23769296 Clinical Trial.
The 2012 BSR and BHPR guideline for the treatment of psoriatic arthritis with biologics.
Coates LC, Tillett W, Chandler D, Helliwell PS, Korendowych E, Kyle S, McInnes IB, Oliver S, Ormerod A, Smith C, Symmons D, Waldron N, McHugh NJ; BSR Clinical Affairs Committee & Standards, Audit and Guidelines Working Group and the BHPR. Coates LC, et al. Among authors: mcinnes ib. Rheumatology (Oxford). 2013 Oct;52(10):1754-7. doi: 10.1093/rheumatology/ket187. Epub 2013 Jul 25. Rheumatology (Oxford). 2013. PMID: 23887065 No abstract available.
637 results